BCL2 and melanoma: Thus, BH3 mimetics for targeting Bcl-2, Bcl-xL, and Bcl-w (ABT-737, -263, -199) have been developed, and their combination with vemurafenib has resulted in enhanced apoptosis and reduced cell viability in BRAF-mutant melanoma cells [51,52].